Report overview
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.
This report aims to provide a comprehensive presentation of the global market for Recombinant Erythropoietin Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Erythropoietin Drugs. This report contains market size and forecasts of Recombinant Erythropoietin Drugs in global, including the following market information:
Global Recombinant Erythropoietin Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Recombinant Erythropoietin Drugs Market Sales, 2018-2023, 2024-2029, (KG)
Global top five Recombinant Erythropoietin Drugs companies in 2022 (%)
The global Recombinant Erythropoietin Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
rhEPO Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Recombinant Erythropoietin Drugs include Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd and LG Life Sciences Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Erythropoietin Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Erythropoietin Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Erythropoietin Drugs Market Segment Percentages, by Type, 2022 (%)
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Global Recombinant Erythropoietin Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Erythropoietin Drugs Market Segment Percentages, by Application, 2022 (%)
Chronic Kidney Disease
Cancer Related Anemia
Others
Global Recombinant Erythropoietin Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Erythropoietin Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Erythropoietin Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Erythropoietin Drugs revenues share in global market, 2022 (%)
Key companies Recombinant Erythropoietin Drugs sales in global market, 2018-2023 (Estimated), (KG)
Key companies Recombinant Erythropoietin Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Erythropoietin Drugs, market overview.
Chapter 2: Global Recombinant Erythropoietin Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Erythropoietin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Erythropoietin Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Erythropoietin Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
